Vitiligo research conferences play an important role in shaping how patient care evolves over time. At these international meetings, you’ll see dermatologists, researchers, immunologists, pharmaceutical experts, and patient advocacy groups coming together to share the latest scientific findings and treatment updates. Many of the therapies and approaches you eventually see in clinics are first presented, discussed, and refined in these settings before they ever reach routine practice.
For you as someone following or involved in clinical care, the impact of these conferences might not always feel immediate, but it is often happening in the background. The conversations you hear about new research can gradually influence how vitiligo is diagnosed, how disease activity is monitored, and how treatment decisions are made. Over time, these insights often filter into updated clinical guidelines and help improve long-term patient outcomes.
As you look at the bigger picture, you’ll notice that these conferences act as a bridge between research and real-world care. They encourage collaboration between specialists and help ensure that new evidence is carefully evaluated before being applied in practice. In the end, the discussions taking place at these events often shape the way you approach vitiligo management, even if the changes feel gradual rather than immediate.
Why Vitiligo Conferences Matter
Vitiligo conferences give you a valuable platform where specialists from around the world come together to share knowledge, research findings, and clinical experience. At these meetings, you’ll often see experts discussing new insights in genetics, immunology, pigmentation biology, and emerging treatment options. This kind of collaboration helps to speed up scientific progress in a way that wouldn’t be possible in isolation.
Without these conferences, you’d likely see research developments spreading much more slowly across the medical community. International meetings help you stay up to date with rapidly evolving treatment strategies and evolving scientific understanding. The shared learning that happens in these spaces ultimately supports more informed decision-making and better patient care worldwide.
These events also encourage stronger cooperation between researchers and practising dermatologists, which is essential for real-world impact. You’ll notice that ideas discussed in laboratories can move more efficiently into clinical practice when there’s active communication between both sides. In the end, it’s this exchange of knowledge that helps drive meaningful progress in how vitiligo is understood and managed.
How Research Becomes Clinical Practice
Many treatments don’t move straight into everyday clinical use the moment they’re discovered. Instead, you’ll often see early research findings first presented at conferences, where experts carefully review and discuss safety, effectiveness, and longer-term outcomes. This stage is important because it allows open debate and peer input, helping to refine ideas before they move any further.
If the early results look promising, you’ll usually see them followed up with larger and more detailed clinical studies. Over time, as more evidence builds, treatment guidelines can gradually evolve. This step-by-step approach ensures that anything introduced into practice has been properly tested, keeping patient safety at the centre of decision-making.
For you as a clinician or someone following medical progress, conferences essentially act as the starting point for future standards of care. They help you understand which innovations are gaining traction and which still need more evidence before becoming mainstream. In this way, scientific scrutiny and ongoing discussion play a key role in shaping the treatments you may eventually use in routine practice.
The Role of International Collaboration
Vitiligo research benefits significantly from international collaboration because you’re dealing with a condition that affects people across all regions and populations. At conferences, you’ll see experts from different countries coming together to compare patient outcomes, treatment approaches, and research methods. This diversity of perspective helps you build a more complete and balanced understanding of the disease.
Different healthcare systems often observe slightly different patterns in how vitiligo presents, progresses, or responds to treatment. When you share these observations internationally, it becomes easier to identify trends and refine clinical knowledge. This exchange of information often leads to better-designed studies that are more representative and clinically meaningful.
International partnerships also open up wider opportunities for research funding and make it easier to recruit patients for clinical trials. When you have larger, more diverse study groups, the evidence generated tends to be stronger and more reliable. Ultimately, this global cooperation helps push the field forward and supports more effective progress in vitiligo care and research.
Better Understanding of Autoimmunity
If you’re living with Vitiligo, you may have heard that it is now understood mainly as an autoimmune condition. At modern dermatology conferences, researchers increasingly focus on how your immune system can mistakenly target melanocytes the cells responsible for producing skin pigment. This shift in understanding has completely changed how vitiligo is viewed and treated in medicine.
- From cosmetic view to immune-based understanding: You may still come across older explanations that treated vitiligo mainly as a cosmetic or psychological issue. However, current research shows that it is driven largely by immune system activity. This has helped move the condition firmly into the field of immunology rather than surface-level skin change alone.
- How your immune system is involved: In vitiligo, certain immune cells become overactive and mistakenly attack pigment-producing cells. Conferences often explore how cytokines and inflammatory signals contribute to this process. These immune pathways are now key targets for new treatments.
- Why this matters for treatment development: Because the condition is now understood as immune-mediated, research has opened up entirely new treatment possibilities. You may see more therapies designed to calm or modify specific immune responses rather than just treating the skin surface.
- A major shift in medical thinking: Immunology now plays a central role in how vitiligo is studied and managed. Instead of focusing only on appearance, clinicians are increasingly looking at the underlying biological processes driving pigment loss. This deeper understanding is shaping modern treatment strategies.
Better understanding of autoimmunity has therefore transformed vitiligo care. You benefit from this progress through more targeted research, more sophisticated therapies, and a clearer scientific explanation of the condition. Ultimately, this shift is helping move treatment towards approaches that address the root cause rather than just the visible changes.
Advances in Genetic Research
Genetic research is one of the key areas you’ll see regularly discussed at vitiligo conferences. Scientists are continuously working to identify genes linked to immune regulation and melanocyte function, which helps you better understand why some people develop vitiligo while others do not, even when exposed to similar triggers. These insights are gradually building a clearer picture of the biological mechanisms behind the condition.
As this knowledge develops, you’ll notice increasing interest in how genetic susceptibility could support earlier diagnosis and more personalised treatment approaches. Researchers are also using genetic data to understand different disease subtypes, which is helping to move the field towards more precise and targeted care. In this way, genetics is becoming an important part of the broader shift towards precision medicine in dermatology.
Although genetic testing is not yet part of routine care for vitiligo, you’ll often hear it discussed at conferences as a potential future tool. Ongoing research is steadily expanding what we know in this area, and while it’s still early, the long-term possibilities are considered promising. As evidence grows, you may eventually see genetics playing a more direct role in guiding treatment decisions.
How JAK Inhibitors Changed the Conversation
One of the most significant recent developments you’ll hear about at vitiligo conferences is the emergence of JAK inhibitor therapies. These treatments target specific immune signalling pathways involved in vitiligo progression, and early conference presentations were key in bringing global attention to their potential. You’ll often find that this is where the first meaningful discussions about their clinical relevance began.
When early trial data was shared, you saw encouraging results in some patients, particularly in terms of repigmentation. This naturally generated a lot of interest within the dermatology community. At the same time, you’ll notice that much of the discussion focused on striking the right balance between effectiveness and long-term safety, which remains a central consideration.
As more evidence has emerged over time, JAK inhibitors have gradually moved closer to clinical use in carefully selected patients. Conferences have played an important role in shaping how these treatments are understood, shared, and interpreted across the global medical community. In many ways, this is a clear example of how innovation often begins in scientific forums before it reaches everyday clinical practice.
Phototherapy Research Updates
Phototherapy remains one of the most established treatments for vitiligo, and you’ll still see it featured regularly at international conferences. Researchers often present updated studies looking at how treatment frequency, dosing schedules, and different delivery methods can be fine-tuned to improve outcomes. These discussions help you understand how even long-standing therapies can continue to evolve with new evidence.
A growing area of interest is how phototherapy can be combined with newer medical treatments. You’ll hear researchers exploring whether combination approaches may enhance repigmentation rates in some patients compared to phototherapy alone. This is an active and evolving area of study, with ongoing trials helping to clarify the most effective protocols.
For you in clinical practice, conference findings often translate into small but meaningful adjustments in how phototherapy is used. Even subtle refinements in dosing or scheduling can make a real difference to patient comfort and treatment effectiveness. In this way, continuous research and shared learning help you deliver more optimised and up-to-date care.
The Growing Importance of Early Treatment
At vitiligo conferences, you’ll increasingly hear discussions about how important early intervention can be. Researchers are exploring the idea that treating vitiligo sooner, particularly when the disease is still active, may improve the chances of achieving meaningful repigmentation. There’s also a growing focus on slowing or preventing progression, rather than only reacting once it has spread.
You’ll often see studies presented that look closely at how disease activity influences treatment response. For example, stable vitiligo may respond differently compared to rapidly progressing disease, which means timing can play a key role in outcomes. This is helping clinicians better understand when certain therapies are likely to be most effective.
As a result, you’ll notice a shift in how dermatologists approach assessment and monitoring in everyday practice. Earlier diagnosis and more proactive management are increasingly encouraged, with a stronger focus on identifying activity as early as possible. In many ways, prevention and early control are becoming central to how vitiligo care is evolving.
Understanding Disease Stability
At international vitiligo conferences, you’ll often hear a strong focus on disease stability because it plays a key role in treatment planning. Stable vitiligo generally refers to a stage where pigment loss has stopped progressing over a period of time, and you’ll find that certain treatments tend to work more effectively when the condition is in this phase.
You’ll also see researchers presenting new ways to measure disease activity more accurately. This includes improved scoring systems, imaging techniques, and clinical assessment tools designed to help you track subtle changes over time. The goal is to make evaluation more consistent, so treatment decisions are based on clearer and more reliable evidence.
By understanding stability more precisely, you can personalise treatment strategies in a more meaningful way. This is becoming increasingly important in dermatology, where individualised care is seen as the key to better outcomes. In practice, improved assessment of disease activity helps you choose the right treatment at the right time, which ultimately supports more effective and targeted care.
Surgical Treatment Innovations
At vitiligo conferences, you’ll often hear discussions around surgical options for stable vitiligo, especially in cases where medical treatments haven’t produced the desired results. Procedures such as melanocyte transplantation and skin grafting are continually being refined, and specialists regularly share updates on improved techniques and better ways of selecting suitable patients.
A key focus in these research discussions is improving the consistency of repigmentation outcomes while also reducing the risk of complications. You’ll notice that surgical innovations in vitiligo care are highly specialised, but they continue to develop steadily as new evidence and clinical experience are shared at international meetings. Conferences play an important role in helping experts fine-tune these techniques.
For you as a patient or clinician, these options are generally considered only when vitiligo is stable and not responding to other treatments. In such cases, careful assessment by experienced specialists is essential to decide whether surgery is appropriate. Overall, these advances show how even highly specialised treatments continue to evolve through ongoing research and collaboration.
The Psychological Impact of Vitiligo
If you’re living with Vitiligo, you may find that the impact goes beyond the skin. At modern dermatology conferences, there is increasing recognition that the condition can affect your confidence, self-image, and emotional wellbeing. Because of this, psychological support is now seen as an important part of overall care, not just an optional extra.
- Impact on confidence and self-image: Visible changes in your skin can sometimes affect how you feel about your appearance. You may notice fluctuations in confidence, especially when patches appear on more visible areas. This emotional response is widely recognised in clinical discussions today.
- Anxiety, stress, and social experiences: Conferences often highlight how you may experience anxiety or stress linked to social situations or concerns about how others perceive your skin. In some cases, social stigma can also influence emotional wellbeing, depending on cultural or personal context.
- Quality of life considerations: Researchers now place strong emphasis on quality-of-life measures, not just clinical improvement. You may be asked about how vitiligo affects your daily life, relationships, and emotional health, as this helps guide more holistic care.
- More integrated psychological support: Psychological care is increasingly being included alongside medical treatment. This might involve counselling, support groups, or simply more structured communication with your clinician. The aim is to support both your skin and your emotional wellbeing.
This broader understanding has changed how clinicians approach vitiligo in everyday practice. You are now more likely to be treated in a way that considers both physical and emotional aspects of the condition. Compassionate, patient-centred care is increasingly seen as essential in dermatology. Ultimately, this shift helps ensure that treatment focuses not only on skin improvement, but also on your overall quality of life.
Skin of Colour and Vitiligo Research
Vitiligo affects all skin types, but you’ll often hear at conferences that it can appear more noticeable in darker skin tones due to the contrast between affected and unaffected areas. Because of this, there’s an increasing focus on understanding how the condition presents across different skin types and ensuring that clinical research reflects this diversity more accurately.
You’ll also see researchers discussing how treatment outcomes, psychological impact, and even diagnostic patterns may vary between populations. This is an important area of focus because better representation in studies helps you build a more accurate and complete understanding of how vitiligo behaves in real-world settings. In turn, this strengthens the reliability of research findings and supports fairer, more effective care.
As these conversations continue, you’ll notice a clear shift towards more inclusive study designs that include a wider range of skin types and patient backgrounds. This broader representation helps ensure that future treatments are tested across diverse populations, which ultimately improves care quality on a global scale. In many ways, inclusivity in research is becoming a key driver of progress in vitiligo understanding and treatment.
Paediatric Vitiligo Discussions
At specialist conferences, you’ll often hear that children with vitiligo present unique challenges that require a slightly different approach compared to adults. Researchers regularly discuss how early-onset vitiligo may behave differently, as well as how treatment responses and safety considerations can vary in younger patients. There’s also a strong emphasis on understanding the wider impact on families, not just the child.
You’ll notice that much of the conversation focuses on balancing effective treatment with long-term safety. In paediatric cases, you’re often encouraged to take a gentler, more cautious approach, ensuring that therapies are both suitable and well-tolerated over time. This is why paediatric dermatology continues to evolve as a distinct and carefully considered area within vitiligo care.
For you as a clinician or someone following this field, these discussions help refine how younger patients and their families are supported in everyday practice. Early intervention strategies are receiving increasing attention, particularly when it comes to managing disease activity safely and effectively. Overall, childhood vitiligo care remains a major focus, with ongoing research aiming to improve outcomes while prioritising safety and quality of life.
The Role of Artificial Intelligence
Artificial intelligence is starting to play a noticeable role in vitiligo research and diagnosis, and you’ll increasingly hear it discussed at international conferences. Experts are exploring how imaging technology and machine learning could help you assess disease progression more accurately, as well as potentially predict how a patient might respond to different treatments. Digital dermatology as a whole is expanding quite rapidly alongside these developments.
You may find that AI tools are being positioned as a way to improve diagnostic accuracy and make monitoring more consistent over time. This could be particularly useful in reducing variation between assessments and supporting more structured clinical decision-making. However, most of these applications are still in the evaluation phase, and researchers are continuing to test how reliable and practical they are in real-world settings.
Even though these systems are still emerging, conference discussions suggest that AI is likely to become increasingly important in future dermatological care. You’ll see ongoing work focused not only on improving performance but also on making these tools usable in everyday clinical workflows. Overall, it’s a fast-moving area where innovation continues to accelerate and gradually shape how you approach vitiligo care and research.
Biomarkers and Personalised Medicine
At vitiligo conferences, you’ll often hear a growing focus on biomarkers that could help predict disease activity or treatment response. Researchers are actively exploring biological signals that might give you clearer insight into how the condition behaves in different patients. This area is becoming a key part of the wider move towards personalised medicine.
If reliable biomarkers are identified, they could help you understand in advance which patients are more likely to respond to specific treatments. This would allow for more targeted and efficient treatment planning, reducing the need for trial-and-error approaches. In turn, you could potentially avoid unnecessary therapies and focus on options that are more likely to be effective for each individual.
Although this field is still developing and requires further research, conference presentations continue to highlight encouraging progress and future potential. You’ll see increasing discussion around how individualised care might become more central in vitiligo management over time. Overall, it’s an expanding area of research that could significantly improve how you approach treatment decisions in the future.
Safety Monitoring of New Therapies
Whenever new treatments for vitiligo emerge, you’ll notice that long-term safety quickly becomes a central topic at conferences. Researchers regularly present updated findings on side effects, monitoring needs, and how durable treatment responses are over time. This careful evaluation is essential before any therapy can be widely adopted in everyday clinical practice.
A key part of these discussions is balancing how effective a treatment is with how safe it remains in the long run. You’ll often hear this especially in relation to therapies that affect the immune system, where ongoing monitoring is crucial. The aim is always to ensure that innovation doesn’t come at the cost of patient safety, which is why responsible development is so strongly emphasised.
These safety-focused conversations play an important role in shaping clinical guidelines and influencing prescribing decisions. For you as a clinician or someone following treatment developments, conferences provide a clear understanding of both the potential benefits and the possible risks of new therapies. In the end, this cautious and evidence-driven approach helps support safer and more effective outcomes for patients.
The Importance of Clinical Trials
If you’re following developments in Vitiligo, you may hear a lot about clinical trials at international conferences. These studies are essential because they test new treatments in a structured and scientific way before they become widely available. Researchers use these trials to understand what actually works, what is safe, and how different patients respond.
- Why clinical trials matter: You may benefit in the future from treatments that are currently still being tested. Clinical trials help determine whether new therapies are effective enough and safe enough to move into everyday clinical practice.
- Sharing early research findings: At conferences, researchers often present early or preliminary results from ongoing studies. This helps other specialists understand what is emerging in the field and how treatment approaches may change over time.
- Improving treatment development: Clinical trials are the main way new vitiligo treatments are developed and refined. They allow scientists to compare different approaches and identify which ones offer the best outcomes for repigmentation and disease control.
- Encouraging global collaboration: You’ll often see hospitals, universities, and pharmaceutical companies working together across countries. This collaboration improves the quality of research by involving larger and more diverse patient groups, which makes results more reliable.
- Raising awareness of new options: Conferences also help raise awareness about therapies that may not yet be widely available. This ensures clinicians stay informed about what is coming next in vitiligo care and how it might benefit you in the future.
Clinical trials therefore play a central role in moving vitiligo treatment forward. You benefit indirectly from this research, even if you’re not personally involved in a study, because it helps bring safer and more effective treatments into everyday practice. Ultimately, strong clinical research is what drives real progress in long-term vitiligo care.
How Conferences Influence Treatment Guidelines
Medical guidelines don’t change overnight they evolve gradually as new evidence builds up over time. At vitiligo conferences, you’ll often see early data, emerging trial results, and expert interpretations being shared, all of which contribute to shaping how future recommendations may develop. Guideline committees usually keep a close watch on these discussions to understand where the field is heading.
As research findings become more robust and consistent across different studies, you may eventually see official recommendations being updated. This process can influence how treatments are used in everyday practice, including what becomes standard care and what remains more specialised. In this way, evidence-based care develops step by step rather than through sudden change.
For patients, this means you may benefit indirectly from conference discussions even years later, once early insights have been fully validated and incorporated into clinical guidelines. Scientific dialogue at these meetings plays a quiet but powerful role in shaping future medical standards. Ultimately, progress takes time, but it steadily moves care forward in a more informed and effective direction.
Patient Advocacy and Conference Participation
At many modern vitiligo conferences, you’ll find that patient advocacy groups and individuals living with vitiligo are actively involved in the discussions. Their input is incredibly valuable because it helps you and other researchers understand what the condition is really like beyond clinical data alone. Patient voices are increasingly being recognised as an essential part of shaping research and care.
A lot of advocacy-focused conversations centre around issues such as treatment access, emotional wellbeing, and the social stigma that can come with visible skin conditions. When you include these perspectives, it often shifts research priorities in more meaningful and patient-centred directions. It reminds you that scientific progress isn’t just about biological outcomes, but also about lived experience.
As patient involvement continues to grow, you’ll notice a stronger push towards more compassionate and practical approaches in healthcare. This collaboration between patients, clinicians, and researchers helps you build a fuller understanding of vitiligo and its impact. Ultimately, modern care is becoming more inclusive, with real-world experiences playing a bigger role in shaping future directions.
Social Media and Faster Knowledge Sharing
Social media has significantly changed how conference insights spread within the dermatology community. You’ll often see key findings, early study results, and expert opinions shared globally within hours of being presented. This rapid exchange helps you stay updated on emerging developments much more quickly than in the past.
For you as a clinician or researcher, this means you can now follow major conference updates even if you’re not physically attending the event. Access to educational content has become far more open and immediate, allowing you to stay connected with ongoing discussions and evolving scientific ideas in real time.
At the same time, you’ll notice that experts continue to emphasise the need for careful interpretation of early findings. Not all preliminary results are ready for clinical application, so full data review and peer validation remain essential. In this way, faster knowledge sharing is balanced with responsible communication, ensuring that accuracy and scientific integrity are maintained.
Why Continuous Research Matters
Vitiligo research is still evolving, and you’ll often hear at conferences just how much there is yet to understand about the condition. Even though significant progress has already been made, researchers continue to explore disease mechanisms, how long treatments remain effective, and whether better prevention strategies could be developed. Ongoing research is essential if you want care to keep improving over time.
Each conference builds on previous findings while also introducing new questions and directions for future study. You’ll notice that scientific progress in this field rarely comes from a single breakthrough. Instead, it happens through steady, incremental advances that gradually deepen understanding and improve clinical practice. This step-by-step progress is just as important as major discoveries.
Ultimately, continuous research benefits patients by expanding treatment options, improving understanding of the disease, and refining long-term care strategies. For you as part of the broader clinical or research community, sustained collaboration is what keeps innovation moving forward. In many ways, progress in vitiligo care depends on this ongoing commitment to shared scientific effort.
FAQs:
1. What actually happens at vitiligo conferences?
At vitiligo conferences, specialists from around the world come together to share research, clinical experiences, and early treatment findings. You’ll often see new ideas being discussed long before they reach everyday clinics. It’s a space where science and real-world practice meet.
2. Why should you care about what is presented at these meetings?
Even if you’re not directly involved, these conferences can influence the care you eventually receive. You’re benefiting from treatments and approaches that are shaped through these discussions. It’s essentially where future vitiligo care begins to take form.
3. Do new vitiligo treatments start at conferences?
Yes, many new treatments are first introduced at conferences in the form of early research or trial results. You’ll hear about promising therapies years before they become widely available. These early discussions help decide what moves forward into larger studies.
4. How do conferences improve vitiligo treatment options?
They allow experts to compare research findings, debate results, and refine treatment strategies. You benefit because only the most promising and safe approaches move forward. Over time, this leads to better and more effective care options.
5. Are conference findings used immediately in clinics?
No, most findings go through further testing before being used in everyday practice. You’ll usually see them progress through clinical trials and guideline reviews first. This careful process helps ensure treatments are safe and effective.
6. How do conferences influence JAK inhibitor treatments?
JAK inhibitors gained attention through early presentations at conferences where researchers shared trial data. You’ll find that these discussions helped shape how the treatment is studied and used today. They’re now being carefully refined for specific patient groups.
7. Why is international collaboration so important in vitiligo research?
It brings together data from different countries, skin types, and healthcare systems. You get a more complete understanding of how vitiligo behaves globally. This shared knowledge helps improve accuracy and treatment development.
8. Do conferences help improve diagnosis as well as treatment?
Yes, they don’t just focus on treatment but also on improving diagnosis and disease tracking. You’ll see new tools and assessment methods being introduced and tested. This helps doctors make more accurate and consistent decisions.
9. How do these conferences affect your treatment in the long term?
Over time, insights from conferences become part of updated medical guidelines. You may not see immediate changes, but your treatment gradually improves as evidence builds. It’s a slow but steady process of refinement.
10. Will vitiligo treatment change quickly because of conferences?
Not instantly changes usually happen step by step as research is confirmed. You’ll see gradual improvements rather than sudden shifts. This ensures that any new approach reaching you is properly tested and reliable.
Final Thoughts: How International Vitiligo Conferences Influence Patient Care
Vitiligo conferences play a much bigger role in your care than you might realise. They act as the starting point for many of the treatments, ideas, and clinical approaches that eventually make their way into everyday dermatology practice. While changes may feel gradual, you’re actually seeing the result of years of international collaboration, research sharing, and careful scientific evaluation.
What really matters is how these meetings help shape safer, more targeted, and more personalised care over time. You’ll see new therapies being explored, existing treatments being refined, and a stronger focus on understanding vitiligo as an autoimmune and complex condition. All of this contributes to more informed decision-making and steadily improving patient outcomes.
Ultimately, conferences help bridge the gap between research and real-world treatment, ensuring that what reaches you in clinic is both evidence-based and carefully tested. As this global knowledge continues to grow, you can expect vitiligo care to become even more precise and patient-focused in the future. If you’re thinking about excessive vitiligo treatment in London, you can contact us at London Dermatology Centre to book a consultation with one of our specialists or explore more via our Vitiligo treatment in London page.
References:
1. Wang Y, Zhang L, Chen J. (2025). Biomolecular pathways in vitiligo: oxidative stress and melanocyte dysfunction. https://www.mdpi.com/2218-273X/16/4/612
2. Li W, Dong P, Zhang G. (2025). https://www.mdpi.com/1467-3045/47/3/191
3. Speeckaert R, Li X, Zhang H. (2025). Immune and biological changes during treatment in non-segmental vitiligo and relation to repigmentation. https://www.sciencedirect.com/science/article/pii/S0022202X25023504
4. Harris JE. (2024). Vitiligo Pathogenesis and Emerging Targeted Therapies. https://pubmed.ncbi.nlm.nih.gov/38417409/
5. Ju HJ, Bae JM. (2024). Bridging Molecular Mechanism and Clinical Practice in Vitiligo Treatment: An Updated Review. https://pubmed.ncbi.nlm.nih.gov/38417409/